Zymeworks Posts $2.28 Per-Share Profit in Third Quarter
ZYME sits 93% above its 52-week low of $16.003.
Summary
Zymeworks reported third-quarter EPS of $2.28, a swing to profit that follows the FDA approval of Ziihera for first-line HER2-positive gastroesophageal adenocarcinoma in August and the $250M milestone payment from Jazz Pharmaceuticals it triggered. The quarter produced $256.5M in revenue and $173.7M in net income. The company also closed its $929M acquisition of Theravance Biopharma in September and issued 2026 revenue guidance of $278M at that time, and it has since raised its 2026 revenue and EBITDA guidance. The stock is trading near its 52-week high of $31.49, so the print lands with expectations already elevated.
At the time of this announcement, ZYME was trading at $30.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $16.00 to $31.49. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.